Testing a targeted immune therapy for EGFR-mutant glioblastoma
Part of Cancer clinical trials.
This Phase 1 trial tests BRiTE, a custom immune “match” therapy designed to attack glioblastoma cells that have a specific EGFRvIII change. It’s for adults with newly diagnosed or recurring grade 4 glioblastoma, aiming to see safety and whether the treatment can shrink or control tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- Your glioblastoma is grade 4 and has the EGFRvIII mutation, confirmed from your most recent diagnosis.
- Your brain tumor area on MRI/CT is small enough (no more than 4 cm at the widest point) before surgery or at first recurrence.
- You can get MRI with contrast (or have only mild contrast allergy like rash).
- Your blood counts, kidney, and liver lab tests are high enough for treatment.
- You must agree to use reliable birth control (if pregnancy is possible) and a caregiver must attend clinic visits on the treatment schedule.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized immune cell treatment for a glioblastoma brain tumor that has a specific marker called EGFRvIII. The cells are made in a lab and given by infusion, and the study aims to see if they can safely target and attack the tumor.
This Phase 1 trial tests a new immune treatment made from your own immune cells to attack glioblastoma (a brain tumor), especially tumors with a specific EGFR change called EGFRvIII. It mainly focuses on safety and early signs of effectiveness, and some participants will also need surgery/biopsy and an implanted port for the treatment.
This trial tests a special immune cell treatment (CAR-T cells) that targets two proteins found on glioblastoma cells. It is for patients whose tumor has come back or not responded to standard treatments.
This early trial tries to find which medicines might work best for your specific glioblastoma, by testing drugs on cancer “stem cell” samples. If the test finds promising drug options, it may guide a more personalized treatment approach.
This trial tests whether two immunotherapy drugs, nivolumab and relatlimab, can help treat glioblastoma (GBM), a type of brain tumor. It is for people newly diagnosed or who haven't had radiation or chemotherapy yet and are scheduled for surgery.
This Phase 1/2 trial tests two experimental treatments delivered through a thin catheter placed in the brain for people with newly diagnosed glioblastoma (GBM). The goal is to see whether the treatment can be given safely and whether it may shrink or control the tumor after standard chemotherapy and radiation.
Hear when a new Newly Diagnosed Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.